Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly across different ages and early-life risk profiles. This evidence gap constrains precision in treatment decisions and…
Continue Reading
News Source: medicalxpress.com
Leave a Reply